JP2019536440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536440A5 JP2019536440A5 JP2019518302A JP2019518302A JP2019536440A5 JP 2019536440 A5 JP2019536440 A5 JP 2019536440A5 JP 2019518302 A JP2019518302 A JP 2019518302A JP 2019518302 A JP2019518302 A JP 2019518302A JP 2019536440 A5 JP2019536440 A5 JP 2019536440A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- item
- polypeptide
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023006458A JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404718P | 2016-10-05 | 2016-10-05 | |
| US62/404,718 | 2016-10-05 | ||
| PCT/US2017/055421 WO2018067874A1 (en) | 2016-10-05 | 2017-10-05 | Variant actriib proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006458A Division JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536440A JP2019536440A (ja) | 2019-12-19 |
| JP2019536440A5 true JP2019536440A5 (enExample) | 2020-11-12 |
| JP7280182B2 JP7280182B2 (ja) | 2023-05-23 |
Family
ID=61831930
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518302A Active JP7280182B2 (ja) | 2016-10-05 | 2017-10-05 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JP2023006458A Active JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006458A Active JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11267865B2 (enExample) |
| EP (1) | EP3523328A4 (enExample) |
| JP (2) | JP7280182B2 (enExample) |
| KR (2) | KR102595559B1 (enExample) |
| CN (1) | CN110036025B (enExample) |
| AU (3) | AU2017338916B2 (enExample) |
| BR (1) | BR112019006918A2 (enExample) |
| CA (1) | CA3039525A1 (enExample) |
| MA (1) | MA46471A (enExample) |
| WO (1) | WO2018067874A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017338916B2 (en) * | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| EP3788067A4 (en) | 2018-05-03 | 2022-01-19 | Acceleron Pharma Inc. | NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES |
| AU2019262139A1 (en) * | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Multispecific binders of TGFβ-superfamily ligands and uses thereof |
| IL278546B2 (en) * | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| US20220089683A1 (en) * | 2018-06-15 | 2022-03-24 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
| CN109293763B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 水貂激活素b蛋白及其制备与应用 |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| US20230183319A1 (en) * | 2020-02-03 | 2023-06-15 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| EP4121088A4 (en) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| CA3179834A1 (en) * | 2020-06-25 | 2021-12-30 | David S. Block | Ace2-fc fusion proteins and methods of use |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| US20240181007A1 (en) * | 2021-01-08 | 2024-06-06 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
| EP4469489A4 (en) | 2022-01-28 | 2026-04-08 | 35Pharma Inc | Type IIB Variants of the Activin Receptor and Their Uses |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0105014B1 (en) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| EP0169016B2 (en) | 1984-07-16 | 2004-04-28 | Celtrix Pharmaceuticals, Inc. | Polypeptide cartilage-inducing factors found in bone |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0830459B1 (en) | 1995-04-11 | 2007-01-24 | The General Hospital Corporation | Reverse two-hybrid systems |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| ES2320603T3 (es) | 1997-07-30 | 2009-05-25 | Emory University | Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos. |
| JP2003517580A (ja) | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
| CA2558478A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CN105963695A (zh) | 2008-05-02 | 2016-09-28 | 阿塞勒隆制药公司 | 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物 |
| KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| CN102548617B (zh) | 2009-03-30 | 2017-11-07 | 阿塞勒隆制药公司 | Bmp‑alk3拮抗剂和促进骨生长的用途 |
| CN107267520A (zh) * | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| KR102170682B1 (ko) | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| CN102712696A (zh) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| DK3520805T3 (da) | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| WO2013063536A1 (en) | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| HK1225742A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| JP2017509647A (ja) | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| EP3131931B1 (en) * | 2014-04-18 | 2020-10-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| CN114699529A (zh) * | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| EP3280435B1 (en) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| WO2016205370A1 (en) | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| AU2017293778B2 (en) | 2016-07-07 | 2022-03-24 | Acceleron Pharma Inc. | TGF-beta superfamily heteromultimers and uses thereof |
| EP3522912A4 (en) | 2016-10-05 | 2020-10-14 | Acceleron Pharma Inc. | HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES |
| AU2017338916B2 (en) | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
-
2017
- 2017-10-05 AU AU2017338916A patent/AU2017338916B2/en active Active
- 2017-10-05 MA MA046471A patent/MA46471A/fr unknown
- 2017-10-05 CA CA3039525A patent/CA3039525A1/en active Pending
- 2017-10-05 JP JP2019518302A patent/JP7280182B2/ja active Active
- 2017-10-05 KR KR1020197012902A patent/KR102595559B1/ko active Active
- 2017-10-05 US US16/340,048 patent/US11267865B2/en active Active
- 2017-10-05 KR KR1020237036672A patent/KR102761094B1/ko active Active
- 2017-10-05 BR BR112019006918-6A patent/BR112019006918A2/pt active Search and Examination
- 2017-10-05 CN CN201780074935.6A patent/CN110036025B/zh active Active
- 2017-10-05 EP EP17859219.2A patent/EP3523328A4/en active Pending
- 2017-10-05 WO PCT/US2017/055421 patent/WO2018067874A1/en not_active Ceased
-
2022
- 2022-03-07 US US17/687,934 patent/US12240887B2/en active Active
- 2022-03-11 AU AU2022201698A patent/AU2022201698A1/en not_active Abandoned
-
2023
- 2023-01-19 JP JP2023006458A patent/JP7617962B2/ja active Active
-
2024
- 2024-02-05 AU AU2024200684A patent/AU2024200684A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11905322B2 (en) | Engineered PD-1 variants | |
| JP2022527635A5 (enExample) | ||
| Steverding | The transferrin receptor of Trypanosoma brucei | |
| Peng et al. | Targeting VEGF–neuropilin interactions: A promising antitumor strategy | |
| JP2025138715A5 (enExample) | ||
| Hynes et al. | Integrin heterodimer and receptor complexity in avian and mammalian cells. | |
| EP3030264B1 (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
| JP2019506166A5 (enExample) | ||
| JP2018525006A5 (enExample) | ||
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2021512624A (ja) | 抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造 | |
| JP2020505034A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2021502807A5 (enExample) | ||
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| CA2828811A1 (en) | Multivalent heteromultimer scaffold design and constructs | |
| AU2013289881A1 (en) | Multivalent heteromultimer scaffold design and constructs | |
| JP2021512615A5 (enExample) | ||
| JP2014508510A5 (enExample) | ||
| JP2022510276A5 (enExample) | ||
| JP2013505713A5 (enExample) | ||
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| JP2019536439A5 (enExample) | ||
| JP2021535727A5 (enExample) | ||
| JP2019530441A5 (enExample) |